Read twice and referred to the Committee on Agriculture, Nutrition, and Forestry.
The bill amends the Farm Security and Rural Investment Act of 2002 to expand and strengthen USDA’s BioPreferred/biobased markets program. It adds new statutory definitions (e.g., bio-attributed product, biobased plastic, bioproduct, plant-based product), requires lifecycle greenhouse gas information and annual updates to federal procurement targets for biobased-only contracts, and directs federal procurement guidance, training, verification, and federal catalog updates to track biobased purchases.
Scope and enforceability of federal procurement mandates: liberals/centrists see opportunity to spur markets; conservatives see mandates as costly federal overreach.
Relative to its intended legislative type, this bill is a substantive statutory amendment package that is largely well-structured: it defines terms, amends procurement and labeling rules, creates a task force with deadlines, and builds reporting and verification mechanisms into existing law.
The bill amends the Farm Security and Rural Investment Act of 2002 to expand and strengthen USDA’s BioPreferred/biobased markets program.
It adds new statutory definitions (e.g., bio-attributed product, biobased plastic, bioproduct, plant-based product), requires lifecycle greenhouse gas information and annual updates to federal procurement targets for biobased-only contracts, and directs federal procurement guidance, training, verification, and federal catalog updates to track biobased purchases.
The bill authorizes USDA public marketing and education activities (including accepting non‑federal contributions), creates a temporary Biobased Task Force to coordinate USDA programs and produce a study and recommendations, extends certain program dates, and creates a new enforceable labeling prohibition against misuse of covered bioproduct terms while preserving certain confidentiality protections for business information.
Judged by content alone, the bill is a moderately scoped, technocratic effort to strengthen a federal biobased procurement and labeling program with explicit rural economic development goals—features that tend to attract bipartisan backing. It does not require major new mandatory appropriations, contains several implementation deadlines and stakeholder processes, and avoids highly polarizing policy areas. However, the bill does impose additional procurement expectations and administrative tasks across federal agencies, and it modifies labeling rules with enforcement consequences; these technical and budgetary concerns raise the bar for unanimous support, particularly in the Senate. The measure therefore has a reasonable chance if advanced through committees and paired with stakeholder engagement or included in a broader legislative vehicle, but it is not certain to pass on its own.
Relative to its intended legislative type, this bill is a substantive statutory amendment package that is largely well-structured: it defines terms, amends procurement and labeling rules, creates a task force with deadlines, and builds reporting and verification mechanisms into existing law.
Scope and enforceability of federal procurement mandates: liberals/centrists see opportunity to spur markets; conservatives see mandates as costly federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and enforceability of federal procurement mandates: liberals/centrists see opportunity to spur markets; conservatives see mandates as costly federal overreach.
A mainstream progressive would likely view the bill favorably overall because it uses federal purchasing power to boost markets for renewable agricultural materials, supports rural jobs, and requires lifecycle greenhouse gas considerations.
They would welcome stronger procurement targets, reporting and verification, public education, and coordination across USDA research and economic units.
However, they would be wary of provisions that allow non‑federal contributions, confidentiality protections for business data, and the allowance for alternate definitions, which could enable industry influence or greenwashing if not tightly constrained.
A pragmatic moderate would generally view the bill as a sensible use of federal procurement policy to support domestic manufacturing and rural economies, provided costs and administrative burdens are reasonable.
They will appreciate the emphasis on standardization (ASTM D‑6866), reporting, verification, training, and coordination within USDA — all of which increase accountability.
Their main concerns are the potential administrative complexity for procuring agencies, unclear fiscal implications, and ensuring the lifecycle greenhouse gas assessments are practical and comparable across products.
A mainstream conservative would be skeptical of expanding federal procurement mandates and new USDA program activity that directs federal purchasing and labeling rules.
While they might welcome domestic job creation and manufacturing, many conservatives would view the bill as an expansion of federal influence in markets, with potential cost and regulatory burdens on agencies and firms.
They are likely to object to mandatory annual increases in biobased procurement, additional training and reporting requirements, and new labeling prohibitions that could be seen as regulatory overreach.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Judged by content alone, the bill is a moderately scoped, technocratic effort to strengthen a federal biobased procurement and labeling program with explicit rural economic development goals—features that tend to attract bipartisan backing. It does not require major new mandatory appropriations, contains several implementation deadlines and stakeholder processes, and avoids highly polarizing policy areas. However, the bill does impose additional procurement expectations and administrative tasks across federal agencies, and it modifies labeling rules with enforcement consequences; these technical and budgetary concerns raise the bar for unanimous support, particularly in the Senate. The measure therefore has a reasonable chance if advanced through committees and paired with stakeholder engagement or included in a broader legislative vehicle, but it is not certain to pass on its own.
The bill has not accumulated any surfaced votes yet.
Scope and enforceability of federal procurement mandates: liberals/centrists see opportunity to spur markets; conservatives see mandates as…
Judged by content alone, the bill is a moderately scoped, technocratic effort to strengthen a federal biobased procurement and labeling pro…
Relative to its intended legislative type, this bill is a substantive statutory amendment package that is largely well-structured: it defines terms, amends procurement and labeling rules, creates a task force with deadl…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.